









Markets
/
Stocks
/
nasdaq-glue
/

Monte Rosa Therapeutics Inc

GLUE

12.070USD

-0.780-6.07%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

744.93MMarket Cap

30.82P/E TTM



Monte Rosa Therapeutics Inc

12.070

-0.780-6.07%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Monte Rosa Therapeutics Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Monte Rosa Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

13 / 407

Overall Ranking

80 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

16.200

Target Price

+26.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Monte Rosa Therapeutics Inc Highlights

StrengthsRisks

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Growing

The company is in a growing phase, with the latest annual income totaling USD 75.62M.

Overvalued

The company’s latest PE is 31.32, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 66.58M shares, increasing 2.48% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 55.40K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 8.45, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 23.19M, representing a year-over-year increase of 394.01%, while its net profit experienced a year-over-year increase of 59.44%.

Score

Industry at a Glance

Previous score

8.45

Change



Financials

7.60

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.51

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.28

Key Metrics

Free cash flow

No Data

Monte Rosa Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.26, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 31.32, which is 43.57% below the recent high of 44.97 and 123.27% above the recent low of -7.29.

Score

Industry at a Glance

Previous score

7.26

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.44, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Monte Rosa Therapeutics Inc is 17.00, with a high of 19.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

16.200

Target Price

+26.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Monte Rosa Therapeutics Inc

GLUE

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 9.38, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 14.45 and the support level at 8.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.62

Change

-0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.208

Buy

RSI(14)

67.290

Neutral

STOCH(KDJ)(9,3,3)

82.640

Neutral

ATR(14)

0.889

High Vlolatility

CCI(14)

66.872

Neutral

Williams %R

26.889

Buy

TRIX(12,20)

2.337

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

12.572

Sell

MA10

11.564

Buy

MA20

10.579

Buy

MA50

7.817

Buy

MA100

6.373

Buy

MA200

5.814

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 107.81%, representing a quarter-over-quarter increase of 5.70%. The largest institutional shareholder is PRFDX, holding a total of 6.23M shares, representing 10.09% of shares outstanding, with 11.82% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

7.69M

T. Rowe Price Associates, Inc.

Star Investors

6.23M

-4.92%

BVF Partners L.P.

5.66M

Versant Ventures

5.65M

Baker Bros. Advisors LP

4.92M

Avoro Capital Advisors LLC

3.73M

-19.82%

Suvretta Capital Management, LLC

3.36M

BlackRock Institutional Trust Company, N.A.

3.36M

+4.12%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 2.45, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.